Erik Bissessar
Gründer bei Eribis Pharmaceuticals AB
Ursprung des Netzwerks ersten Grades von Erik Bissessar
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Eribis Pharmaceuticals AB
Eribis Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Eribis Pharmaceuticals AB, ('Eribis') was founded by Erik Bissessar and co-founded by Herman Krapf. Karolinska Development is the primary investing partner. The basis of Eribis is the Company's unique competence in developing peptides for the pharmacological use for treatment of several clinical indications. The company's main focus is on developing new, effective and safe drugs for the treatment of cardiovascular disorders, in particular acute myocardial ischemia, and also for surgical preconditioning. The Company is based on research in the fields of peptide chemistry and pharmacology. The main goal for Eribis is to develop its Candidate Drug to meet the market's demand for new and improved treatment in the field of cardio-protection. Other medical indications may be considered at a later stage.
3
| Private Company | Pharmaceuticals: Major | 3 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Erik Bissessar
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
IBM | Packaged Software | Sales & Marketing | |
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Corporate Officer/Principal | |
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
Helax AB
Helax AB Medical SpecialtiesHealth Technology Part of Sotera Health Co., Helax AB is a Swedish company that provides products for radiation-based cancer treatment. The company is based in Uppsala, Sweden. The company was founded by Hans Erik Dahlin. Helax was acquired by Nordion (Canada), Inc., part of Sotera Health Co. from July 30, 2018 on May 04, 1999. | Medical Specialties | Sales & Marketing | |
University of Uppsala | College/University | Corporate Officer/Principal | |
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Investment Managers | Private Equity Investor | |
FLERIE INVEST AB | Pharmaceuticals: Major | Corporate Officer/Principal | |
ONCOPEPTIDES AB | Pharmaceuticals: Major | Director/Board Member | |
Karyon-CTT Oy
Karyon-CTT Oy Miscellaneous Commercial ServicesCommercial Services Karyon-CTT Oy discovers and develops novel and innovative peptide-based tumor targeting systems. Its Targeting Units (TU) are intended for delivery of diagnostic imaging agents or therapeutic compounds to cancer tissue. The company was founded in 2006 and is headquartered in Helsinki, Finland. | Miscellaneous Commercial Services | Director/Board Member | |
MOBERG PHARMA AB | Pharmaceuticals: Major | Corporate Officer/Principal | |
KDev Exploratory AB
KDev Exploratory AB Miscellaneous Commercial ServicesCommercial Services KDev Exploratory AB provides drug discovery solutions. It performs discovery research in various therapeutic areas, such as screening in oncology, neuroscience, lead finding, characterization in inflammation and angiogenesis/age-related macular degeneration. The company was founded by David Jern in 2000 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Chairman | |
Biosergen AS
Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | Biotechnology | Corporate Officer/Principal Chairman | |
LipoCore AB | Corporate Officer/Principal | ||
LIPIDOR AB | Miscellaneous Commercial Services | Director/Board Member | |
Vetenskapsrådet | Corporate Officer/Principal | ||
ASARINA PHARMA AB | Pharmaceuticals: Major | Director/Board Member | |
Umecrine Cognition AB
Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
VICORE PHARMA HOLDING AB | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
KAROLINSKA DEVELOPMENT AB | Financial Conglomerates | Corporate Officer/Principal | |
Biocelex Ltd. Oy | Director/Board Member | ||
MarBiLeads AS
MarBiLeads AS BiotechnologyHealth Technology MarBiLeads AS engages in the development of drug candidates for infections and cancer based on marine microorganisms. The company was founded on December 22, 2010 and is headquartered in Trondheim, Norway. | Biotechnology | Director/Board Member | |
ZICCUM AB | Medical Specialties | Director/Board Member | |
Camber Consulting AB | Chief Executive Officer | ||
Clinstorage AB
Clinstorage AB Miscellaneous Commercial ServicesCommercial Services Clinstorage AB is a Swedish company that specializes in packaging, labeling, and managing the cold chain logistics of drugs. The private company is based in Stockholm, Sweden. The CEO of the company is Ola Camber. | Miscellaneous Commercial Services | Chief Executive Officer | |
Clinproducts AB | Chief Executive Officer | ||
Ola Flink Consulting AB | Chairman |
Statistik
International
Schweden | 30 |
Finnland | 4 |
Norwegen | 3 |
Vereinigte Staaten | 2 |
Sektoral
Health Technology | 20 |
Commercial Services | 7 |
Finance | 3 |
Technology Services | 2 |
Consumer Services | 2 |
Operativ
Director/Board Member | 19 |
Corporate Officer/Principal | 11 |
Chairman | 7 |
Chief Executive Officer | 4 |
Chief Tech/Sci/R&D Officer | 3 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Ola Flink | 19 |
Ola Camber | 15 |
Herman Krapf | 5 |
- Börse
- Insiders
- Erik Bissessar
- Unternehmensverbindungen